Biomedicine in Skolkovo: new residents
Quantum Pharmaceuticals will be engaged in a project in Skolkovo to develop innovative medicines against several viruses, including influenza and HIV with the same mechanism of action (inhibition of matrix proteins of viruses). The company has already completed the development of the first working version of the software and started the development of medicines, in 2011-2012 it is planned to conduct preclinical tests of selected compounds according to international GLP standards. After that, either independently or in partnership with a strategic partner-a Russian pharmaceutical company, the project participants will conduct clinical trials in the Russian Federation according to Russian standards. "Quantum's technological platform is (its) know-how and has no analogues in the world. Quantum has developed and is developing a software platform for drug search based on a three—dimensional protein structure," the foundation said in a statement.
The biotech company OncoMax, a joint project of the Maxwell Biotech Venture Fund and the RVC Seed Investment Fund, has received the status of a participant in the Center for the Development and Commercialization of New Technologies of the Skolkovo Foundation. The decision on this was made at a meeting of the expert board of the Fund, which took place in mid-April.
OncoMax's first product, OM-RCA-01, is intended for targeted therapy of kidney cancer. It selectively affects tumor cells, preventing their growth. According to preliminary data, its effectiveness is higher than that of the most commercially successful drugs of this type. Currently, the drug is at the stage of preclinical trials. OncoMax LLC is a Russian innovative company that is part of the Maxwell Biotech Group biotech holding. The main activity of OncoMax is aimed at the development and introduction to the Russian market of innovative biopharmaceuticals for the recognition and treatment of oncological diseases.
The Universal Biosystems company plans to create tools and technologies for building a unified medical system of a full cycle — from general and differentiated diagnostics to personalized therapy of oncological diseases. According to the authors of the project, the creation and introduction into broad medical practice of tools and techniques of such a system in itself is innovative even in world practice. The original drugs being created currently have no clinical analogues in the world, scientists say.
The Farmalliance company will create a group of medicines with high export potential belonging to a fundamentally new class of N-acyl derivatives of biogenic amines and their analogues. These compounds have anti-inflammatory, antispasmodic, broncholytic effects, and can also be used to treat viral infections, infertility, type 2 diabetes mellitus. The project team began active research of compounds of this class in 2003, at the moment methods of their synthesis have been developed.
The company's know-how is the accumulated knowledge of the relationship between the structure and pharmacological activity of substances from this series of compounds, which allows us to design new candidate molecules with specified pharmacological properties in a targeted manner. Scandic Pharma and specialists from the University of Helsinki are also involved in the research. The project is designed for three years, according to its results, a number of drug candidates who have passed the first phase of clinical trials should be obtained, as well as co-investments for further continuation of clinical research and development of drug production should be attracted.
To be continued?
Portal "Eternal youth" http://vechnayamolodost.ru based on open source materials
27.05.2011